首页> 外文OA文献 >Clinical experience with cefbuperazone in complicated urinary tract infection
【2h】

Clinical experience with cefbuperazone in complicated urinary tract infection

机译:头孢哌拉酮在复杂尿路感染中的临床经验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cefbuperazone (CBPZ) was administered to inpatients with complicated urinary tract infections (UTI) at our department. Clinical efficacy and safety were evaluated in 22 chronic cases by the criteria for evaluation of clinical of antimicrobial agents on urinary tract infection. Overall clinical efficacy was excellent in 8 cases, moderate in 9 cases and poor in 5 cases with an effectiveness rate of 77%. Twenty-four of the 34 strains isolated from the patients were eradicated and eradication rate was 71%. Neither subjective nor objective adverse reactions were observed. Abnormal changes in laboratory tests were found in 9 patients, but were probably not related to CBPZ administration. Judging from these results, CBPZ is considered to be an effective and safe antibacterial for the treatment of complicated UTI.
机译:头孢哌酮(CBPZ)在我们科室用于患有复杂尿路感染(UTI)的患者。根据评估尿路感染抗菌药物临床标准,评估了22例慢性病例的临床疗效和安全性。总体临床疗效优良8例,中度9例,差5例,有效率77%。从患者身上分离出的34株菌株中有24株被根除,根除率为71%。没有观察到主观或客观不良反应。 9名患者的实验室检查出现异常变化,但可能与CBPZ给药无关。从这些结果来看,CBPZ被认为是治疗复杂尿路感染的有效且安全的抗菌剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号